Diversity of cell death signaling pathways in macrophages upon infection with modified vaccinia virus Ankara (MVA)

被引:9
|
作者
Klaas, Lioba [1 ]
Vier, Juliane [1 ]
Gentle, Ian E. [1 ]
Hacker, Georg [1 ]
Kirschnek, Susanne [1 ]
机构
[1] Univ Freiburg, Med Ctr, Inst Med Microbiol & Hyg, Fac Med, Freiburg, Germany
关键词
PROGRAMMED NECROSIS; DENDRITIC CELLS; NECROPTOSIS; PHOSPHORYLATION; APOPTOSIS; CASPASES; PROTEIN; DEGRADATION; ACTIVATION; INDUCTION;
D O I
10.1038/s41419-021-04286-3
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Regulated cell death frequently occurs upon infection by intracellular pathogens, and extent and regulation is often cell-type-specific. We aimed to identify the cell death-signaling pathways triggered in macrophages by infection with modified vaccinia virus Ankara (MVA), an attenuated strain of vaccinia virus used in vaccination. While most target cells seem to be protected by antiapoptotic proteins encoded in the MVA genome, macrophages die when infected with MVA. We targeted key signaling components of specific cell death-pathways and pattern recognition-pathways using genome editing and small molecule inhibitors in an in vitro murine macrophage differentiation model. Upon infection with MVA, we observed activation of mitochondrial and death-receptor-induced apoptosis-pathways as well as the necroptosis-pathway. Inhibition of individual pathways had a little protective effect but led to compensatory death through the other pathways. In the absence of mitochondrial apoptosis, autocrine/paracrine TNF-mediated apoptosis and, in the absence of caspase-activity, necroptosis occurred. TNF-induction depended on the signaling molecule STING, and MAVS and ZBP1 contributed to MVA-induced apoptosis. The mode of cell death had a substantial impact on the cytokine response of infected cells, indicating that the immunogenicity of a virus may depend not only on its PAMPs but also on its ability to modulate individual modalities of cell death. These findings provide insights into the diversity of cell death-pathways that an infection can trigger in professional immune cells and advance our understanding of the intracellular mechanisms that govern the immune response to a virus.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax® using proteome microarrays and development of recombinant protein ELISAs
    Hermanson, Gary
    Chun, Sookhee
    Felgner, Jiin
    Tan, Xiaolin
    Pablo, Jozelyn
    Nakajima-Sasaki, Rie
    Molina, Douglas M.
    Felgner, Philip L.
    Liang, Xiaowu
    Davies, D. Huw
    VACCINE, 2012, 30 (03) : 614 - 625
  • [42] Zinc-finger antiviral protein (ZAP) is a restriction factor for replication of modified vaccinia virus Ankara (MVA) in human cells
    Peng, Chen
    Wyatt, Linda S.
    Glushakow-Smith, Shira G.
    Lal-Nag, Madhu
    Weisberg, Andrea S.
    Moss, Bernard
    PLOS PATHOGENS, 2020, 16 (08)
  • [43] Extracellular vesicles containing virus-encoded membrane proteins are a byproduct of infection with modified vaccinia virus Ankara
    Spehner, Daniele
    Drillien, Robert
    VIRUS RESEARCH, 2008, 137 (01) : 129 - 136
  • [44] Improving the immunogenicity of modified vaccinia virus Ankara (MVA) vaccine vector by deletion of the vaccinia E5R gene encoding a dominant cGAS inhibitor
    Deng, Liang
    Yang, Ning
    Wang, Yi
    Dai, Peihong
    Shuman, Stewart
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [45] Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses
    Kreijtz, J. H. C. M.
    Suezer, Y.
    de Mutsert, G.
    van den Brand, J. M. A.
    van Amerongen, G.
    Schnierle, B. S.
    Kuiken, T.
    Fouchier, R. A. M.
    Loewer, J.
    Osterhaus, A. D. M. E.
    Sutter, G.
    Rimmelzwaan, G. F.
    VACCINE, 2009, 27 (45) : 6296 - 6299
  • [46] Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice
    Brewoo, Joseph N.
    Powell, Tim D.
    Jones, Jeremy C.
    Gundlach, Nancy A.
    Young, Ginger R.
    Chu, Haiyan
    Das, Subash C.
    Partidos, Charalambos D.
    Stinchcomb, Dan T.
    Osorio, Jorge E.
    VACCINE, 2013, 31 (14) : 1848 - 1855
  • [47] Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins
    Olszewska, W
    Suezer, Y
    Sutter, G
    Openshaw, PJM
    VACCINE, 2004, 23 (02) : 215 - 221
  • [48] Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model
    Weidinger, G
    Ohlmann, M
    Schlereth, B
    Sutter, G
    Niewiesk, S
    VACCINE, 2001, 19 (20-22) : 2764 - 2768
  • [49] Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines
    Amara, RR
    Villinger, F
    Staprans, SI
    Altman, JD
    Montefiori, DC
    Kozyr, NL
    Xu, Y
    Wyatt, LS
    Earl, PL
    Herndon, JG
    McClure, HM
    Moss, B
    Robinson, HL
    JOURNAL OF VIROLOGY, 2002, 76 (15) : 7625 - 7631
  • [50] Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects
    Howles, Sarah
    Guimaraes-Walker, Ana
    Yang, Hongbing
    Hancock, Gemma
    di Gleria, Katalin
    Tarragona-Fiol, Tony
    Hayes, Peter
    Gilmour, Jill
    Bridgeman, Anne
    Hanke, Tomas
    McMichael, Andrew
    Dorrell, Lucy
    VACCINE, 2010, 28 (45) : 7306 - 7312